Overview

Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)

Status:
Unknown status
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
A multi-center, randomized, 4-arm, placebo-controlled, double-blind efficacy study of ARYS-01 (sorivudine) cream 3%.
Phase:
Phase 2
Details
Lead Sponsor:
aRigen Pharmaceuticals, Inc.
Treatments:
Acyclovir
Sorivudine
Valacyclovir